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Understanding Modern Vaccines:
Perspectives in VaccinologyBiographiesPaolo Bonanni, MD: Paolo Bonanni is Full Professor of Hygiene in
the Faculty of Medicine at the University of Florence, Italy. He is also
Director of the University’s postgraduate course on ‘Vaccines and
Vaccination Strategies’ which was established in 2001 and has
since been undertaken by over 500 Italian MDs. Professor Bonanni
graduated in medicine and surgery in 1985 and gained two
specialisations in hygiene and preventive medicine at the University
of Genoa, Italy. From 1992 to 2000 he was Associate Professor in
the Faculty of Medicine at the University of Florence. His scientiﬁc
activity has covered the epidemiology and prevention of infectious
diseases, particularly viral hepatitis, diphtheria, tetanus, pertussis,
inﬂuenza, measles, rubella, varicella and, most recently, bacterial
invasive diseases and HPV, including clinical trials and economic
evaluation of vaccination strategies. Professor Bonanni has been
a member of the National Vaccination Commission of the Italian
Ministry of Health, and he acts as an expert consultant for the
European Centre for Disease Prevention and Control (ECDC). He is
standing advisor for the Viral Hepatitis Prevention Board (VHPB), an
international independent committee of experts in viral hepatitis
prevention. Professor Bonanni has received several grants from the
Italian Ministry of Education, University and Research for projects 2011 Elsevier B.V.
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xiv UNDERSTANDING MODERN VACCINESrelating to vaccine-preventable infections and was responsible for
a research unit in three EU-funded projects: ANTRES (antibiotic
resistance in Latin America), EURO-HEPNET (feasibility of an EU
network for surveillance of vaccine-preventable hepatitis) and
VACSATC (vaccine safety, attitudes and training). Professor
Bonanni has authored or co-authored 200 scientiﬁc papers
published in international and national journals.
Wen-Fang Cheng, MD, PhD: Wen-Fang Cheng is a Professor at
the Graduate Institute of Oncology at the National Taiwan University
College of Medicine, and Gynaecologic Oncologist at the
Department of Obstetrics and Gynecology, National Taiwan
University Hospital. Professor Cheng received his medical degree
and PhD from the National Taiwan University College of Medicine.
He completed his fellowship in the Training Programme of
Gynecologic Oncologists at the National Health Research Institute,
Taiwan. Professor Cheng has also served as a Postdoctoral Fellow
at the Department of Pathology, Johns Hopkins University School of
Medicine, as well as an observer for the Kelly Gynecologic
Oncology Service in the Department of Obstetrics and Gynecology
at the Johns Hopkins Medical Institutions, Maryland, USA. He is
a member of several national and international professional bodies,
including the International Gynecologic Cancer Society, Taiwan
Association of Gynecologic Oncology and the Taiwan Association
of Obstetrics and Gynecology. Professor Cheng’s clinical interests
include the use of ultrasound, surgery and chemotherapy in the
treatment of gynaecologic cancers. His current research interests
focus on tumour immunology and tumour biology. The author of
over 100 peer-reviewed articles in national and international medical
journals, Professor Cheng has received several awards in
recognition of his innovative work in gynaecologic cancers such as
cervical, uterine and ovarian carcinoma.
Anthony Cunningham, MBBS, MD: Tony Cunningham is Director
of the Westmead Millennium Institute for Medical Research at the
Westmead Hospital and of the Centre for Virus Research in Sydney,
Australia. He is also Professor of Research Medicine and Sub-Dean
(Research) at the Western Clinical School at the University of
BIOGRAPHIES xvSydney. Professor Cunningham is also Director of the Australian
Centre for HIV and Hepatitis Virology Research which is directly
funded by the Australian Department of Health. He trained in
infectious diseases, clinical virology and virology research at the
University of Melbourne, Australia, and as a Postdoctoral Fellow
at Stanford University, USA. Professor Cunningham’s major
research interests are in HIV and herpes simplex virus biology and
immunology, especially in relation to the development of vaccines
and microbicides. He has also published numerous original and
review articles on epidemiology, antiviral therapy and vaccines for
herpes simplex and varicella/zoster viruses, has participated in
many international round-table meetings and often acts as
a consultant for global pharma on these topics. Professor
Cunningham has published more than 250 peer-reviewed primary
scientiﬁc articles and 50 invited reviews or chapters in various
journals or books. His publications have been cited over 7000 times.
Nathalie Garçon, PharmD, PhD: Nathalie Garçon is Vice President
andHeadofGlobal Adjuvant Centre for VaccineDevelopment at GSK
Biologicals. Following the successful completion of two PhDs, one in
biological pharmacy and the other in immunotoxicology and
immunopharmacology, Dr Garçon moved to the UK for 1 year as
a Postdoctoral Research Fellow at the Royal Free Hospital in London,
undertaking research on liposomes in vaccines. She then moved to
the USA where she spent 4 years at Baylor College of Medicine in
Houston, Texas, ﬁrst as a Postdoctoral Research Fellow, then as
Assistant Professor, working on vaccine delivery systems and
immunopotentiators. Dr Garçon joined SmithKline Beecham
Biologicalse now GlaxoSmithKline Biologicalse in 1990, where she
set up and led the vaccine adjuvant and formulation group. She
provides leadership within GSK Biologicals in the ﬁeld of adjuvants,
from discovery to registration and commercialisation of adjuvanted
vaccines. DrGarçon’s expertise in vaccinology extends from research
to manufacturing, in particular immunology, adjuvant and formulation
technologies, analytical methods, animal experimentation and
toxicology/safety evaluation and testing. She has authored over 40
papers and book chapters, and holds more than 200 patents.
xvi UNDERSTANDING MODERN VACCINESOberdan Leo, PhD: Professor Oberdan Leo is Full Professor at the
Université Libre de Bruxelles (ULB), Belgium, where he teaches
Immunology and Cellular Biology at the Faculté des Sciences and
has directed a research group at the Laboratory of Animal
Physiology. Professor Leo is also Assistant Professor at the
Université de Mons, Belgium. Since 1999, he has served as
President of the Belgian Immunological Society. Professor Leo’s
major research interests focus on the relationship between
metabolism and the inﬂammatory response and the analysis of
T helper subset differentiation pathways. His contributions in these
areas have resulted in more than 115 publications in top-ranked
journals including Nature Medicine, the Journal of Experimental
Medicine, Proceedings of the National Academy of Sciences (USA)
and the Journal of Immunology. In 2004 GSK Biologicals initiated
a publiceprivate partnership with the ULB and the Walloon Region
which supports the Institute for Medical Immunology and Professor
Leo has been a consultant for the company for several years.
Geert Leroux-Roels, MD, PhD: Geert Leroux-Roels is Professor of
Medicine and founding Director of the Center for Vaccinology
at Ghent University and Hospital, Belgium. After obtaining his
medical degree in 1976 from Ghent University, he trained in
internal medicine while performing doctoral research on
enzyme-immunoglobulin complexes in the Laboratory of Clinical
Pathology at Ghent University Hospital. Over the past 25 years,
Professor Leroux-Roels and his team have been studying the human
immune response towards the hepatotropic viruses, HBV and HCV,
and have made an important contribution to the understanding of
mechanisms of non-responsiveness to hepatitis B vaccines. Since
the discovery of HCV in 1989, he and his team have been examining
the human immune response to this virus in order to understand the
mechanisms underlying resolution and persistence. Professor
Leroux-Roels’ fascination with viruses and immunity has led to
a growing interest and involvement in clinical vaccine evaluation. In
the past two decades, more than 100 novel and improved vaccines
and a series of innovating adjuvant systems have been clinically
evaluated at theCenter for Vaccinology. He is the author or co-author
BIOGRAPHIES xviiof numerous articles published in international peer-reviewed
journals, including The Lancet, Hepatology and Vaccine.
José Ignacio Santos, MD, MSc: José Ignacio Santos is Professor
and Head of the Infectious Diseases Unit at the Department of
Experimental Medicine, School of Medicine, National Autonomous
University of Mexico. Professor Santos completed his medical and
paediatric training at Stanford University, USA, and clinical
immunology and infectious diseases training at the University of
Utah, USA. Prior to his current appointment, Professor Santos was
General Director at the Hospital Infantil de México Federico Gómez
(2004e2009). From 1997e2004 he was Director of Mexico’s
National Infant and Adolescent Health Program and Immunization
Program as well as Mexico’s liaison member of the Advisory
Committee on Immunization Practices of the Centers for Disease
Control and Prevention. Professor Santos’ research and public
health interests have focused on paediatric infectious diseases and
the evaluation and introduction of new vaccines. He works with
several international health agencies including the International
Center for Diarrheal Research (ICDDRB); the Measles Working
Group of the Strategic Advisory Group of Experts (SAGE, the
principal advisory group to the World Health Organization [WHO]
for vaccines and immunisation); the Pediatric Dengue Vaccine
Initiative (PDVI), and the Data and Safety Monitoring Board for the
WHO’s Measles Aerosol Project. Professor Santos is past President
of the Mexican and Pan-American Infectious Diseases Societies,
a Fellow of the Infectious Diseases Society of America (IDSA) and
a member of the advisory group of Pediatric Global Research
Priorities (PGRP) of the American Academy of Pediatrics. He has
authored or co-authored 270 peer-reviewed publications.
Lawrence R Stanberry, MD, PhD: Lawrence Stanberry is the
Reuben S Carpentier Professor and Chairman of the Department of
Pediatrics at the College of Physicians and Surgeons at Columbia
University, USA, and Pediatrician-in-Chief of the New York
Presbyterian Morgan Stanley Children’s Hospital, USA. Professor
Stanberry is an internationally recognised authority on vaccine
development and viral diseases. He has served on numerous
xviii UNDERSTANDING MODERN VACCINESadvisory and review panels including Chair of the Vaccine Study
Section and the Pediatrics Review Panel at the National Institutes of
Health (NIH). Professor Stanberry has received research funding
from the NIH, the Centers for Disease Control and Prevention,
numerous vaccine, pharmaceutical and biotech companies, and
the Bill and Melinda Gates Foundation. His areas of research
include the development of prophylactic and therapeutic vaccines
and his laboratory provided the ﬁrst experimental evidence to
support the concept of vaccine immunotherapy for the treatment of
persistent viral infections. Professor Stanberry has authored over
200 scientiﬁc articles. He is the Co-editor (with Dr David Bernstein)
of the textbook Sexually Transmitted Diseases: Vaccines,
Prevention, and Control published by Academic Press Ltd, London
(2000) and Co-editor (with Dr Alan Barrett) of the comprehensive
textbook Vaccines for Biodefense and Emerging and Neglected
Diseases published by Elsevier (London) in 2009.
Peter L Stern, PhD: Peter L Stern is Head of the Immunology
Group at Cancer Research UK‘s Paterson Institute for Cancer
Research at the University of Manchester. Professor Stern trained at
University College, London, UK, obtaining his BSc and PhD. He has
previously held research positions as staff scientist at the MRC
Molecular Biology Laboratory, Cambridge, UK, European Molecular
Biology Organization Fellow at the University of Uppsala, Sweden,
Cancer Research Campaign Fellow and Junior Research Fellow at
Linacre College, University of Oxford, UK, lecturer at the Medical
School, University of Liverpool, UK, and Visiting Professor at the
Free University of Amsterdam, The Netherlands. The theme of
Professor Stern’s research has been the investigation of shared
properties of developmental tissues and cancer cells with a view to
identifying new targets for diagnosis, prognosis or therapy. This
focus and application at the translational interface has enabled
ideas to transfer successfully from the bench to the clinic. Examples
include an MVA-based 5T4 oncofoetal antigen vaccine and a 5T4
antibody-based superantigen therapy, both of which are now in
phase III clinical trials. In the ﬁeld of HPV, Professor Stern’s activities
have been directly related to the development of prophylactic and
BIOGRAPHIES xixtherapeutic treatments for patients with HPV-associated anogenital
disease. This has included the design and delivery of clinical and
laboratory analyses of numerous clinical trials of vaccines and
other immunotherapies.
Richard Strugnell, MD, PhD: Richard Strugnell is Professor of
Microbiology in the Department of Microbiology and Immunology at
The University of Melbourne, Australia. Professor Strugnell obtained
his PhD in microbiology from Monash University, Australia in 1985,
then undertook postdoctoral training in Australia and the UK, before
taking up an academic post at Melbourne in 1991. His research
interests are in bacterial pathogenesis, particularly the antibacterial
immune responses that occur during natural infection, and in
response to vaccination. Professor Strugnell’s research focus is
enteric bacteria including Salmonella, Klebsiella and Helicobacter,
and in recent years he has investigated the roles of mucosal
antibodies and Tcells in disease prevention and in the pathological
response to infection. His research on bacterial pathogenesis is
leveraged to identify vaccine targets that can be delivered using
adjuvanted or living vaccine delivery systems to elicit protective
immune responses. Professor Strugnell receives funding support
from the National Health and Medical Research Council of Australia
and was a member of a team supported by the Gates Foundation’s
Grand Challenges in Global Health to develop a recombinant
Salmonella delivery platform for the developing world.
Terapong Tantawichien, MD: Terapong Tantawichien is Professor
in the Division of Infectious Diseases, Department of Medicine at
Chulalongkorn University, Thailand. Professor Tantawichien
received his medical degree from the same university and is
board-certiﬁed in internal medicine and infectious diseases. His
main scientiﬁc and research interests include rabies vaccination,
adolescent and adult immunisation (such as HPV, pertussis and
inﬂuenza), dengue in adults and infections in immunocompromised
hosts. Professor Tantawichien has held positions at King
Chulalongkorn Memorial Hospital and Kuzell Institute, California
Paciﬁc Medical Center, San Francisco, USA. He is former
Secretary-General of the Infectious Diseases Association of
xx UNDERSTANDING MODERN VACCINESThailand and is currently Chief of Division of Infectious Diseases
and Deputy Chairman for Academic Affairs, Department of
Medicine at Chulalongkorn University. Professor Tantawichien is
also Assistant Director at the Queen Saovabha Memorial Institute in
Bangkok, Thailand, and Deputy Chairman of the scientiﬁc
committee of the Royal College of Physicians of Thailand. In 2001,
he was the recipient of the ﬁrst Young Investigator Award from the
Infectious Diseases Association of Thailand. Professor
Tantawichien is the author or co-author of numerous articles
published in international peer-reviewed journals, including The
Lancet, Vaccine and Clinical Infectious Diseases.
Fred Zepp, MD, PhD: Fred Zepp is Medical Director and Chairman
of the Children’s Hospital, Johannes Gutenberg University Mainz,
Germany. He obtained his medical degree as a Research Fellow
and undertook his residency in the Department of Paediatrics at the
same university, where he was appointed Head of Paediatric
Immunology and Infectiology in 1985. After working as a Research
Fellow at the Institute for Immunology in Basel, Switzerland,
Professor Zepp qualiﬁed as a paediatrician. His research focuses
on cell-mediated immune responses to vaccines and candidate
vaccines in infants and adults, immune responses to acute
respiratory tract infection in children and immunology of the
newborn. Professor Zepp has held many professional posts,
including Attending Physician and Assistant Professor of
Paediatrics at Johannes Gutenberg University Mainz. He is former
Chair of the Association for Paediatric Immunology and current
Chair of the advisory board of the ‘Preventive Medicine in
Paediatrics’ Foundation. Professor Zepp is also a member of the
scientiﬁc advisory board of the German Medical Association and
last year was appointed President of the German Society of
Paediatric and Adolescent Medicine. He has published more than
100 original papers and reviews.
